GlassScriptPhysician profile
Utpal Pajvani
NPI 1922257773
$8,817.42
in general payments reported to CMS, 2019-2025
4 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,899 · 2020: $1,190 · 2021: $3,275 · 2024: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,313 · Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,312.50 |
| Food and Beverage | $140.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $6,174.04 | 2019-2021 | |
| Novo Nordisk INC | $1,453.38 | 2024 | |
| Janssen Research & Development, LLC | $1,190.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Utpal Pajvani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.